Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function
Inês Falcão‐Pires,Ana Filipa Ferreira,Fábio Trindade,Luc Bertrand,Michele Ciccarelli,Valeria Visco,Dana Dawson,Nazha Hamdani,Linda W. Van Laake,Frank Lezoualc'h,Wolfgang A. Linke,Ida G Lunde,Peter P. Rainer,Mahmoud Abdellatif,Jolanda Van der Velden,Nicola Cosentino,Alessia Paldino,Giulio Pompilio,Serena Zacchigna,Stephane Heymans,Thomas Thum,Carlo Gabriele Tocchetti
DOI: https://doi.org/10.1002/ejhf.3264
2024-06-05
European Journal of Heart Failure
Abstract:Pathologic and physiologic cardiac remodelling triggers, interventions that can result in different outcomes and factors influencing its trajectory (aetiology, non‐modifiable factors, comorbidities and pre‐interventional myocardial state). The cardiac response to different interventions can span from adverse remodelling (worsening of the cardiac morphofunctional condition), incomplete reverse remodelling (RR) (partial structural and functional improvement of the heart), complete RR (characterized by total structural and functional improvement) and cardiac recovery (when an additional improvement of relevant clinical endpoints, such as no further hospital readmission and improved quality of life, is met). AS, aortic valve stenosis; BNP, B‐type natriuretic peptide; CABG, coronary artery bypass graft; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; LVAD, left ventricular assist device; PCI, percutaneous coronary intervention. Some graphical elements were collected from Flaticon.com. Cardiovascular disease (CVD) is the leading cause of morbimortality in Europe and worldwide. CVD imposes a heterogeneous spectrum of cardiac remodelling, depending on the insult nature, that is, pressure or volume overload, ischaemia, arrhythmias, infection, pathogenic gene variant, or cardiotoxicity. Moreover, the progression of CVD‐induced remodelling is influenced by sex, age, genetic background and comorbidities, impacting patients' outcomes and prognosis. Cardiac reverse remodelling (RR) is defined as any normative improvement in cardiac geometry and function, driven by therapeutic interventions and rarely occurring spontaneously. While RR is the outcome desired for most CVD treatments, they often only slow/halt its progression or modify risk factors, calling for novel and more timely RR approaches. Interventions triggering RR depend on the myocardial insult and include drugs (renin–angiotensin–aldosterone system inhibitors, beta‐blockers, diuretics and sodium–glucose cotransporter 2 inhibitors), devices (cardiac resynchronization therapy, ventricular assist devices), surgeries (valve replacement, coronary artery bypass graft), or physiological responses (deconditioning, postpartum). Subsequently, cardiac RR is inferred from the degree of normalization of left ventricular mass, ejection fraction and end‐diastolic/end‐systolic volumes, whose extent often correlates with patients' prognosis. However, strategies aimed at achieving sustained cardiac improvement, predictive models assessing the extent of RR, or even clinical endpoints that allow for distinguishing complete from incomplete RR or adverse remodelling objectively, remain limited and controversial. This scientific statement aims to define RR, clarify its underlying (patho)physiologic mechanisms and address (non)pharmacological options and promising strategies to promote RR, focusing on the left heart. We highlight the predictors of the extent of RR and review the prognostic significance/impact of incomplete RR/adverse remodelling. Lastly, we present an overview of RR animal models and potential future strategies under pre‐clinical evaluation.
cardiac & cardiovascular systems